Moderna (MRNA) Fundamental Analysis: Revenue, Earnings & Valuation

6.62 / 10

Outperform

Fundamental rating is Outperform with a 6.6/10 score. Strengths include Asset‑MV, Revenue‑MV, Profit‑MV, Cash‑MV and inventory turnover. Weak points are current and fixed asset turnover and a high cost‑of‑sales ratio, leading to a modestly optimistic outlook.

Analysis Checks(6/10)

Revenue-MV

Value-0.50

Score2/3

Weight23.16%

1M Return8.05%

Inventory turnover ratio

Value6.43

Score2/3

Weight-1.22%

1M Return-0.56%

Gross profit margin (%)

Value55.35

Score1/3

Weight0.78%

1M Return0.36%

Profit-MV

Value0.68

Score2/3

Weight18.85%

1M Return6.36%

Income tax / Total profit (%)

Value-1.95

Score2/3

Weight2.37%

1M Return0.98%

Current assets turnover ratio

Value0.27

Score0/3

Weight-3.52%

1M Return-1.61%

Fixed assets turnover ratio

Value0.90

Score1/3

Weight-2.45%

1M Return-1.13%

Cost of sales ratio (%)

Value44.65

Score1/3

Weight-12.83%

1M Return-7.30%

Asset-MV

Value-0.55

Score3/3

Weight56.40%

1M Return15.70%

Cash-MV

Value1.28

Score2/3

Weight18.47%

1M Return6.19%

Is MRNA undervalued or overvalued?

MRNA scores 6.62/10 on fundamentals and holds a Discounted valuation at present. Backed by its -28.87% ROE, -145.16% net margin, -7.22 P/E ratio, 2.35 P/B ratio, and 21.77% earnings growth, these metrics solidify its Outperform investment rating.